Genentech’s Gazyva wins first FDA approval for primary membranous nephropathy

Key highlights
  • Gazyva (obinutuzumab) is approved for adults with primary membranous nephropathy at risk of progression, to induce remission of proteinuria.
  • In the Phase III MAJESTY study, complete remission at week 104 was 36.1% with Gazyva and 5.7% with tacrolimus.
  • Overall remission at week 104 was 50% with Gazyva and 12.9% with tacrolimus.
  • The European Medicines Agency is also reviewing Gazyva for primary membranous nephropathy.

FDA approval

The FDA approved Genentech’s Gazyva (obinutuzumab) for adults with primary membranous nephropathy (pMN) at risk of disease progression, to induce remission of proteinuria. It is the first FDA-approved treatment specifically for the condition.

Phase III results

Approval was based on the Phase III MAJESTY study of 142 adults randomized to Gazyva or tacrolimus. At week 104, complete remission of proteinuria was achieved by 36.1% of patients receiving Gazyva versus 5.7% receiving tacrolimus. Overall remission at week 104 was 50% versus 12.9%. No new safety signals were identified.

Condition and regulatory activity

pMN is a chronic autoimmune disease that damages the kidney’s filtering units, causing protein to leak into urine and potentially leading to irreversible kidney damage and kidney failure. Gazyva is also approved for idiopathic nephrotic syndrome and lupus nephritis. The European Medicines Agency is reviewing data on Gazyva for pMN.

Source: Genentech

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

15 July 2026
Roche: FDA grants Priority Review for Gazyva/Gazyvaro (obinutuzumab) in primary membranous nephropathy

Priority Review follows MAJESTY phase III showing 36.9% complete remission at two years vs 5.7% with tacrolimus; FDA decision expected by Nov 2026.

14 July 2026
Genentech’s Gazyva (obinutuzumab) granted FDA priority review for primary membranous nephropathy

FDA granted priority review for obinutuzumab in pMN after Phase III MAJESTY showed markedly higher complete remission vs tacrolimus; FDA decision expected Nov 2026.

15 February 2026
Genentech's Gazyva Shows Positive Phase III Results in Primary Membranous Nephropathy

Phase III study shows Gazyva achieves significant remission in primary membranous nephropathy, with safety profile consistent and no new signals. Data to be shared with health authorities.

16 February 2026
Roche Reports Positive Phase III Results for Gazyva in Membranous Nephropathy

Phase III study shows Gazyva achieves higher remission rates in membranous nephropathy, with safety consistent and no new signals. Data to be shared with health authorities.

20 April 2026
FDA Accepts Genentech sBLA for Gazyva in SLE

FDA accepted sBLA for an anti‑CD20 in SLE after Phase III ALLEGORY: SRI‑4 responders 76.7% vs 53.5%, higher remission, fewer flares and steroid reduction; decision due Dec 2026.